Audited Financial Results for the Quarter and Year ended on March 31, 2026.

Revenue declinedNet loss reportedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1268.00

prior close

₹1271.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-1.1% vs market

Pharmaceuticals peers, median of 160sector+0.7%-1.3% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-1.7

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.4-1.1+0.7-1.3

Next day

-0.8+1.0-1.8+1.2-2.0

+6.1+2.2+3.9+1.4+4.7

+10.2+2.2+7.9+0.8+9.3

+8.4+3.9+4.5+2.0+6.4

+3.1+4.6-1.5+2.3+0.8

+6.1+3.9+2.2+2.1+3.9

15d

+7.2+3.4+3.8+1.6+5.6

+4.7+10.3-5.6+3.4+1.3

+11.5+10.8+0.7+9.1+2.4

—+14.9—+9.6—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bharat Parenterals reported mixed results for FY26. On a standalone basis, revenue declined 23% to ₹234 crore from ₹304 crore, while net profit fell 39% to ₹16 crore. The company declared a dividend of ₹1 per share. On a consolidated basis, the group reported a net loss of ₹27.3 crore, though this is an improvement from the previous year's loss of ₹43.7 crore. Consolidated revenue remained flat at ₹345 crore. EBITDA margin expanded on a consolidated basis (from 0.79% to 4.58%) but compressed on standalone (from 11.05% to 9.01%). Non-current borrowings increased significantly from ₹7.6 crore to ₹12.2 crore, indicating higher leverage. The statutory auditors issued an unmodified opinion on both standalone and consolidated results.

Likely market impact

The standalone revenue decline and consolidated net loss are concerning for shareholders. The increase in debt levels raises concerns about financial leverage. However, the narrowing of consolidated losses and improved operating cash flow may offer some comfort.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹99.62 Cr	₹104.0 Cr	−4.2%
Operating profit	−₹12.00 Cr	−₹10.50 Cr	loss widened
Profit after tax	−₹8.16 Cr	−₹9.44 Cr	loss narrowed
EBITDA margin	-0.5%	2.1%	−2.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.